Skip to content

    Recently Viewed


      An optometrist at the Singapore National Eye Center performing a vision exam on a young girl

      Helping kids see clearly: Johnson & Johnson Vision teams up with the Singapore Eye Research Institute to launch a new myopia initiative

      Nearsightedness has become an epidemic, but a new three-year partnership among global leaders in myopia research and innovation is poised to help children have a brighter future.

      Share Article
      share to

      All over the world, we are raising an indoor generation of children.

      In America, kids spend, on average, more than 90% of their time indoors; in Singapore, one study showed children spend just three hours a week playing outside. Recent studies have also suggested that as many as 90% of high school graduates in China and other East Asian countries may currently be myopic.

      And that’s no small thing: This lack of sun exposure may be one of the leading causes for the explosion in global rates of myopia, also known as nearsightedness. Researchers suspect nearsightedness may be a response to too much time spent in dim light indoors, focusing on “near work,” like looking at computer and smartphone screens.

      And while myopia might seem like a fixable inconvenience, rather than a global health concern, over time, it can lead to such serious complications as blindness, glaucoma and cataracts.

      Tackling a Growing Health Challenge Together

      The Singapore National Eye Center

      The Singapore National Eye Center

      So this week Johnson & Johnson Vision announced a new research collaboration with the Singapore National Eye Center (SNEC) and the Singapore Eye Research Institute (SERI). This powerful trifecta of world leaders in eye health will share resources, data and trial results to help halt myopia’s alarming progression.

      Helping guide the partnership is Noel Brennan, O.D., Ph.D., Johnson & Johnson Vision Care, Inc. Myopia Control Research Fellow. “We wanted to do something positive to counteract the threat myopia presents to vision problems,” Dr. Brennan says.

      And that means teaming up with experts in the field to maximize impact.

      “SERI and SNEC have a long track record in myopia research, and Johnson & Johnson Vision brings deep expertise in optometry and ophthalmology,” says Professor Wong Tien Yin, medical director of the Singapore National Eye Center and chairman, vice-office of academic and clinical development at the Singapore Eye Research Institute.

      The common perception that myopia is no big deal is the very thing we are fighting. There is no ‘safe’ level when it comes to increased risk of disease.
      Noel Brennan, O.D., Ph.D., Johnson & Johnson Vision Care, Inc. Myopia Control Research Fellow

      The more than $26 million initiative includes funding and in-kind contributions from Johnson & Johnson Vision and SERI, and a grant from the Singapore government.

      The partnership highlights four categories of research, explains Wong: identifying who will get myopia; figuring out the underlying mechanisms that contribute to the disease’s progression; progressing novel therapies that can prevent, slow or stop myopia; and discovering new methods to prevent the onset and progression of myopia-associated disease and vision loss.

      To that end, the researchers will build from their existing knowledge base in corrective contact lenses, orthokeratology (specially designed contact lenses worn overnight) and medication to help identify and ultimately develop next-generation therapies. The joint venture will also emphasize the importance of early intervention, and the need for patient-centric models of care.

      The long-term vision? Creating a healthier generation of kids.

      “The common perception that myopia is no big deal is the very thing we are fighting,” Dr. Brennan says. “There is no ‘safe’ level when it comes to increased risk of disease.”

      More from Johnson & Johnson

      Blue latex-gloved hands holding a beaker filled with yellow liquid

      IBD rates are rising in communities of color. Can these innovators help?

      Scientists aren’t sure what’s behind the upward trend. That’s why Johnson & Johnson Innovation put out the call to address this troubling health disparity.
      DNA illustration genetic material

      Harnessing the human genome is the future of healthcare—and Johnson & Johnson is helping lead the way

      The company’s partnership with the largest human genome sequencing project in the world will increase scientists’ understanding of genetic diseases and help create new interventions. Here, a look at the breakthroughs that have guided the understanding of the power of DNA.
      Health & wellness
      1123 BTN-Lung Cancer-Iede2.jpg
      Health & wellness

      By the numbers: Who gets lung cancer?

      Each year, more people die of lung cancer than colon, breast and prostate cancers combined. Learn how Johnson & Johnson is dedicated to improving outcomes by integrating the company’s MedTech and Innovative Medicine expertise.
      You are now leaving and going to a site with a different privacy policy. Please click below to continue to that site.